Amae Health raises $25M in Series B funding. Amae Health, a San Francisco, CA-based Public Benefit Corporation (PBC) and leader in outpatient treatment for SMI, raised $25m in pre-empted Series B financing, bringing total funding to more than $50m. The round was led by Altos Ventures with participation from all existing investors, including Quiet Capital, Bling Capital, Cedars-Sinai Ventures, Healthier Capital, and 8VC. The company intends to use the funds to accelerate the opening of Amae clinics nationwide, advance its proprietary AI-driven care platform, and support research into schizophrenia, bipolar disorder, and treatment-resistant depression. It will also strengthen partnerships with academic medical centers to expand access to Amae's integrated model of care. Led by Stas Sokolin, Co-Founder and CEO, Amae Health is dedicated to serving Americans living with severe mental illness (SMI) by partnering with health systems nationwide to deliver an outpatient model that combines compassionate, in-person psychiatric care with wraparound support and AI-powered clinical tools. Since opening its first clinic in Los Angeles in 2022, Amae has partnered with health systems including NewYork-Presbyterian, Cedars-Sinai and Stanford Health Care to bring team-based outpatient care to communities in need. To further its mission, Amae has established the Amae Institute, a center for excellence dedicated to advancing care for SMI. The Amae Institute partners with research hospitals and academic experts to develop next-generation treatments and accelerate the scientific progress needed to achieve long-term remission and, ultimately, a cure.

Amae Health announced a $25 million Series B funding round led by Altos Ventures, bringing total funding to over $50 million. The funds will enhance Amae's AI-powered precision-care platform and expand its clinics nationwide. The company aims to transform severe mental illness treatment through a combination of in-person care and AI technology, achieving significant improvements in patient outcomes. The funding will also support research into schizophrenia, bipolar disorder, and treatment-resistant depression.

SAN FRANCISCO, April 21, 2025 /PRNewswire/ -- Amae Health, a psychiatry-led integrated care provider of outpatient physical and behavioral health services for people living with a severe mental illness (SMI), today announced a new groundbreaking collaboration with the Massachusetts General Hospital (MGH) to support the development of the Amae Institute for professional education for care teams providing comprehensive SMI care.MGH clinician-researchers will provide an important contribution to the professional education program for Amae Health's teams. Amae's mission is to create a new standard of care for individuals with SMI and their families. By leveraging a data-driven, integrated approach, Amae combines psychosocial interventions, including therapy, and pharmacologic treatment, health and wellness coaching, primary care services, and recovery-oriented support to deliver comprehensive and transformative care. As part of their efforts to develop a center of excellence for SMI care delivery, Amae has developed the Amae Institute in collaboration with MGH to enhance care delivery from highly trained leaders in academic medicine."The Amae Institute stands as a declaration against the status quo in SMI care, pursuing what others deem too difficult: finding cures for these complex conditions," said Amae Health's Chief Medical Officer, Dr. Scott Fears. "In collaboration with Massachusetts General Hospital, the Amae Institute empowers clinicians with cutting-edge training, merging academic rigor with the scalability of a public benefit corporation to revolutionize mental health treatment